Fingerprint
Dive into the research topics of 'First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
The LIBRETTO-431 Trial Investigators
Research output: Contribution to journal › Article › peer-review
20
Scopus
citations